Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use.
Bouet-Toussaint F, Patard JJ, Gervais A, Genetet N, de la Pintière CT, Rioux-Leclercq N, Toutirais O, Thirouard AS, Ramée MP, Catros-Quemener V. Bouet-Toussaint F, et al. Cancer Immunol Immunother. 2003 Nov;52(11):699-707. doi: 10.1007/s00262-003-0412-9. Epub 2003 Jul 15. Cancer Immunol Immunother. 2003. PMID: 12879292 Free PMC article. Clinical Trial.
Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk.
Cabillic F, Bouet-Toussaint F, Toutirais O, Rioux-Leclercq N, Fergelot P, de la Pintière CT, Genetet N, Patard JJ, Catros-Quemener V. Cabillic F, et al. Among authors: bouet toussaint f. Clin Exp Immunol. 2006 Dec;146(3):518-23. doi: 10.1111/j.1365-2249.2006.03212.x. Clin Exp Immunol. 2006. PMID: 17100773 Free PMC article.
Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy.
Lavoué V, Cabillic F, Toutirais O, Thedrez A, Dessarthe B, de La Pintière CT, Daniel P, Foucher F, Bauville E, Henno S, Burtin F, Bansard JY, Levêque J, Catros V, Bouet-Toussaint F. Lavoué V, et al. Among authors: bouet toussaint f. Int J Cancer. 2012 Aug 15;131(4):E449-62. doi: 10.1002/ijc.27353. Epub 2011 Dec 21. Int J Cancer. 2012. PMID: 22095289
Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.
Bouet-Toussaint F, Cabillic F, Toutirais O, Le Gallo M, Thomas de la Pintière C, Daniel P, Genetet N, Meunier B, Dupont-Bierre E, Boudjema K, Catros V. Bouet-Toussaint F, et al. Cancer Immunol Immunother. 2008 Apr;57(4):531-9. doi: 10.1007/s00262-007-0391-3. Epub 2007 Sep 1. Cancer Immunol Immunother. 2008. PMID: 17764010 Free PMC article.
Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
Cabillic F, Toutirais O, Lavoué V, de La Pintière CT, Daniel P, Rioux-Leclerc N, Turlin B, Mönkkönen H, Mönkkönen J, Boudjema K, Catros V, Bouet-Toussaint F. Cabillic F, et al. Among authors: bouet toussaint f. Cancer Immunol Immunother. 2010 Nov;59(11):1611-9. doi: 10.1007/s00262-010-0887-0. Epub 2010 Jun 26. Cancer Immunol Immunother. 2010. PMID: 20582413 Free PMC article.